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Aminoglycosides are commonly prescribed antibiotics with deleterious side eﬀects to the inner ear. Due to their popular
application as a result of their potent antimicrobial activities, many eﬀorts have been undertaken to prevent aminoglycoside
ototoxicity. Over the years, understanding of the antimicrobial as well as ototoxic mechanisms of aminoglycosides has increased.
These mechanisms are reviewed in regard to established and potential future targets of hair cell protection.
1. Introduction
Aminoglycosides (AGs) are a well-known and successful class
of antibiotics. The initial isolation of streptomycin from
Streptomyces griseus provided the long-sought treatment for
tuberculosis and an eﬀective antibiotic against gram-negative
bacteria [1, 2]. In subsequent years, other AGs were isolated
from Streptomyces spp., commonly integrating the ending
“-mycin” in their nomenclature [3, 4]. With the isolation of
gentamicin from Micromonospora purpurea [5], the ending
“-micin” was implemented to specify the bacterial origin of
the individual AG. In contrast to these organic derivatives of
soil-dwelling bacteria, synthetic AGs such as amikacin could
be developed in vitro [6]. Currently, nine AGs (streptomycin,
neomycin, tobramycin, kanamycin, paromomycin, spectino-
mycin, gentamicin, netilmicin, and amikacin) are approved
by the Food and Drug Administration (FDA) [7].
In addition to their potent antimicrobial eﬃcacy, all AGs
can cause toxic side eﬀects to the kidneys and inner ear.While
damage inflicted by AG on the kidney is usually reversible
[8, 9], damage to the inner ear is permanent [10]. This
nephro- and ototoxicity was initially discovered in the first
clinical trials of streptomycin [11, 12]. Within the inner
ear, streptomycin preferably damages the vestibular organ
[12]. Modification of streptomycin to dihydrostreptomycin,
however, resulted in a shift of ototoxic damage from the
vestibular organ to the cochlea [13]. Generally, each AG
is capable of irreversibly damaging both the auditory and
vestibular organs, but “typically aﬀects one more than the
other” [14]. Gentamicin and tobramycin are predominantly
vestibulotoxic, whereas neomycin, kanamycin, and amikacin
are mainly cochleotoxic [15]. Ototoxic side eﬀects occur
within days or weeks after systemic application and are often
bilateral in presentation [16]. Vestibulotoxicity occurs in up
to 15% of patients after AG administration [17], whereas
cochleotoxicity in 2% to 25% of patients [17, 18]. Diﬀerent
regimens of AG administration and diﬀerent definitions of
ototoxic damage may have contributed to the variation of
incidence [19].
Symptoms of cochleotoxicity include hearing loss and/or
tinnitus, while those of vestibulotoxicity consist of disequi-
librium and dizziness. Unfortunately, these symptoms may
not be detected until after the acute phase of severe infection
and diagnosis is thus delayed. AG cochleotoxicity typically
aﬀects first the high frequency and then extends towards the
lower frequency and ranges over time in a dose-dependent
manner [20, 21]. Because the ultrahigh frequencies of
hearing are not routinely tested (>8 kHz), the true incidence
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of AG-induced hearing loss is often underestimated. Indeed,
when ultra-high frequency testing was performed, hearing
loss was reported in 47% patients with a history of AG
treatment [22].
Despite the nephro- and ototoxic side eﬀects, AGs are still
the most commonly prescribed antibiotics [23, 24]. In the
industrialized world, use of AGs is usually limited to severe
infections including those caused by multidrug resistant
tuberculosis [25, 26]. Neonates frequently receive AGs for
suspected or proven gram-negative infection, as sepsis is
associated with high mortality [27]. In the developing world,
however, AG use has been popular because of their low
cost and potent antibacterial activities, outrivaling more
expensive antibiotics with less severe side eﬀects. There,
AGs are even prescribed as first-line therapy for less severe
conditions such as bronchitis or otitis media [28]. Additional
safety precautions such as blood level monitoring or hearing
tests are also limited [19]. As a result, the incidence of
AG ototoxicity in developing countries may increase in
comparison to the industrialized world.
2. Pharmacokinetics and Antimicrobial
Mechanism of Aminoglycosides
The AG class of compounds consists of an aminocyclitol
moiety with two or more amino sugar rings [29]. A
characteristic quaternary ammonium group makes AGs
polycationic (positive charge) and highly polar [30, 31].
As a result, enteral absorption is poor and AGs are
generally administered parenterally or topically [32]. After
parenteral administration, AG plasma levels peak between
30 and 90 minutes [7, 33]. Drug metabolism is minimal as
approximately 99% of the administered AGs are eliminated
unaltered by glomerular filtration in the proximal tubule
[34, 35]. The plasma half-life of AGs ranges from 1.5 to
3.5 hours [7, 36], but is prolonged in neonates, infants, and
conditions with decreased kidney function [7, 37].
The most common indication to administer AGs is
for empirical treatment of patients with severe infections
such as septicemia, nosocomial respiratory tract infection,
complicated urinary tract infections, and complicated intra-
abdominal infection [25], partly because AGs are shown
eﬀective against aerobic, gram-negative bacteria [38]. AGs
demonstrate an increased selective antimicrobial activity in
an alkaline environment [39]. It has been suggested that
an alkaline pH compromises the bacterial membrane [40,
41], which might facilitate AG penetration into bacteria.
Additionally, AGs have up to 6 amines with pKs varyingmore
than two orders of magnitude, thus making the molecules
much less charged at alkaline pH and so more able to
interact with a lipid environment. Normally, the positively
charged nature of the AG molecule precludes free passage
through lipid barriers such as cell membranes, but promotes
bacterial uptake and rapid binding to negatively charged
lipopolysaccharides (LPS) in the outer membrane of gram-
negative bacteria [42]. By competitive displacing bridging
divalent cations such as Mg2+ or Ca2+, AGs can disrupt
cross-links between adjacent LPS [43]. Such a disruption
damages membrane integrity and leads to blebbing of the
outer membrane, ultimately resulting in transient holes of
the gram-negative cell wall [44, 45]. This formation of holes
in the cell wall facilitates further AG uptake and appears to
significantly contribute to the bactericidal eﬀect of AGs [46].
With this first step, AGs enter the periplasmic space of gram-
negative bacteria in a passive and non-energy-dependent
manner [47]. In a second step (also referred to as energy-
dependent phase I), AGs are transported further through
the inner bacterial membrane in an oxygen-requiring process
[47]. Therefore, uptake is facilitated in aerobic bacteria [47].
Once in the cytosol, AGs interact with the 30S subunit
of bacterial ribosomes [48, 49] in a third and energy-
dependent step (energy-dependent phase II) [47, 50]. At the
30S subunit, AGs bind to the decoding site located at the
A site of the 16S rRNA [51, 52]. Binding of AGs at this
site perturbs the recognition and selection of tRNA during
translation and increases misreading [52, 53]. Furthermore,
binding of AGs inhibits ribosomal translocation [54–56].
Perturbation of both ribosomal translation and transloca-
tion ultimately inhibits protein synthesis. Interestingly, the
aﬃnity for diﬀerent rRNA binding sites varies amongst
diﬀerent classes of AGs [57–59]. This slightly diﬀerent AG-
ribosome interaction, therefore, appears to be beneficial
against bacterial resistance [19].
3. Ototoxicity and Mechanism of
Hair Cell Damage
3.1. Susceptibility and Genetic Predisposition for Amino-
glycoside Ototoxicity. While AGs preferentially target the
bacterial ribosome, the inner ear and kidney are known
to receive collateral damage in many patients receiving
treatment [11, 12]. However, a meta-analysis comparing
once versus multiple-daily regimens of diﬀerent AGs could
not determine a statistical significant correlation between
ototoxicity and treatment regimens [60]. One main suscep-
tibility factor (17%–33% of patients with reported ototoxic
damage [61]) is the genetic predisposition to AG ototoxicity
[62]. The fact that this increased susceptibility was inherited
maternally suggested mitochondrial involvement [62]. This
is compelling in light of the endosymbiotic theory as
mitochondrial ribosomes demonstrate more similarities to
prokaryotic ribosomes than cytosolic ribosomes [63, 64].
Therefore, the small subunit of the mitochondrial ribosome
is one of the primary targeting sites for AGs [48, 49].
Several mutations in mitochondrial DNA are linked
to increased susceptibility to AG ototoxicity [61, 65, 66].
Exposure to AG leads to impairment of RNA translation
within mitochondria through interaction with binding sites
on mitochondrial 12S rRNA [65]. This interaction was
mapped to an adenine-to-guanine mutation at nucleotide
1555 in the 12S rRNA gene [65]. Of additional note, bacterial
resistance mutations are described at this locus [67, 68]. This
mutation increases structural similarity of mitochondrial
rRNA to bacterial rRNA [65], which promotes binding of AG
to mutated mitochondrial 12S rRNA [69, 70]. As a result,
damage can result from decreased protein synthesis [69].
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Although no direct evidence exists to link ototoxicity to an
inhibition of mitochondrial protein synthesis, inhibition of
mitochondrial protein synthesis potentiates AG toxicity [71].
Also, electron microscopy reveals mitochondrial disruption
following AG treatment [72].
This susceptibility mutation has been reported in 17%–
33% of patient with reported AG ototoxicity [61]; in the
general population of the European Union, it is estimated to
be 1 : 500 [73, 74]. Other mutations leading to increased AG
susceptibility have also been described, including C1494T
[66]. The C1494T mutations have varying degrees of pen-
etrance [75], are less common than the A1555G mutation
[76], and are sporadic with multiple origins [77]. In sum, the
prevalence of the most common mutations across varying
ethnic backgrounds is 0.9%–1.8% [76, 78], of which 5%-6%
are sporadic [63, 79, 80].
Although this genetic susceptibility is present in all
organs, the mitochondrial mutations target the cochlea
but not the vestibular organs or the kidneys [81]. This is
intriguing as this selective cochleotoxicity also occurs with
preferably vestibulotoxic AGs such as streptomycin [81]. One
proposed explanation for this phenomenon is that AGs cause
misreading in mitochondrial protein synthesis rather than
direct inhibition of protein synthesis [82] such that tissues
rich in mitochondria would be predominately aﬀected [81].
Exposure to AGs would decrease mitochondrial ATP syn-
thesis resulting in compromised ion pump activity [81, 82].
Reduced ion pump activity in strial intermediate cells could
ultimately lead to a progressive decrease of the endocochlear
potential [81]. This scenario conceivably explains the slow
progression of hearing loss after exposure to AGs observed
in patients with increased genetic susceptibility [81]. The
strial impairment, furthermore, would explain the little eﬀect
on vestibular function in these patients [81]. Interestingly,
the stria vascularis demonstrates extensive degeneration
in syndromal mitochondrial diseases [83]. This further
supports the hypothesis of the stria vascularis as the cochlear
cells targeted by the mitochondrial mutations in patients
with increased genetic susceptibility to AG ototoxicity. An
alternative simple explanation is that susceptibility to the
mitochondrial disease is a function of metabolic demand
so that hair cells operating at higher frequencies will be
more susceptible to a reduced mitochondrial function than
lower frequency cells, that is, cochlea versus vestibular, basal
versus apical, and type I versus type II. Similarly the highly
metabolically active strial cells would also have increased
sensitivity.
In genetically susceptible individuals, it is postulated
that a single injection of AG can cause ototoxic damage
[84], implying that genetic factors can reduce the thresh-
old concentration at which AGs cause damage [61]. At
higher concentrations or more frequent doses of AG, the
incidence of ototoxic damage exceeds the prevalence of
genetic predispositions [76, 81, 85]. Although in vitro, a
clear relationship between damage and AG concentration is
observed, the extent of ototoxic damage in vivo does not seem
to correlate with AG concentration in targeted tissues [86].
This discrepancy requires further evaluation.
3.2. Route of Aminoglycosides into Hair Cells. After systemic
administration, AGs are detected in the cochlea within
minutes. Fluorescently labeled gentamicin was detected in
the stria vascularis 10 minutes after injection in mouse [87].
In the stria vascularis, the fluorescently tagged gentamicin
increased over time mainly in marginal cells, but also in
intermediate and basal cells as well as fibrocytes, plateauing
after 3 hours [87]. These observations suggest that gentam-
icin enters the inner ear fluids from the strial capillaries
through the strial marginal cells [87]. In the organ of
Corti, fluorescence from labeled gentamicin starts increasing
1 hour after systemic injection. Hair cells demonstrate
fluorescent gentamicin intracellularly after 3 hours [87].
Earlier studies demonstrated similar pharmacokinetics in rat
and guinea pig [88, 89]. In rat cochlear tissues, gentamicin
concentrations were measured by a radioimmunoassay and
peaked 3 hours after systemic application [89]. In guinea pig,
gentamicin appeared in the stria vascularis 30 minutes after
systemic injection. In outer hair cells (OHCs), gentamicin
was detected after 30 minutes and peaked 6 hours after
systemic injection [88]. Although these studies had diﬀerent
specific time points for measurements, they are roughly in
agreement as to the time course of uptake into cochlear
tissues [87–89]. Based on the cochlear structures, where AGs
are located, entry into various cochlear structures suggests a
complex uptake mechanism (Figure 1).
Both endocytosis and transport through ion channels
are proposed to mediate AGs uptake into sensory hair
cells. While some publications describe endocytosis as the
mechanism of entry into hair cells [90, 91] others advocate
for the mechanoelectrical transducer (MET) channel located
at the top of hair cell stereocilia [92–94]. The endocytic
mechanism of AG entry arose because researchers observed
the appearance of vesicles in the subcuticular region of hair
cells after systemic injection in guinea pigs [95]. Hashino and
Shero observed kanamycin in intracellular vesicles 27 hours
after systemic injection in chicken [90]. These findings were
interpreted as evidence for endocytosis as mechanism of AG
uptake as the vesicle membranes contained cationic ferritin,
a membrane bound marker [90]. However, no diﬀerences
in intravesicular AG, compared to a control group, were
observed until 12 hours after injection [90].
Myosin7a was hypothesized to play a role in endocytosis-
mediated AG uptake due to its concentrated expression at
the apical part of hair cells in a region with high amounts
of vesicles known as the pericuticular necklace [91, 96]. The
lack of AG uptake inMyosin7a6j mutant mice was considered
evidence supporting AG toxicity mediated by endocytosis
[91]. Further investigation found that Myosin7a-deficient
hair cells exhibit closed MET channels at rest, confounding
initial interpretations [97].
Furthermore, the rate of endocytosis correlates with
temperature and, therefore, is decreased in hypothermic
conditions [98]. AG uptake demonstrates little temperature-
dependent kinetics, indicating a minor relevance of endo-
cytosis in the process [99]. Instead, there is strong evidence
that AGs enter hair cells through the MET channel located
at the top of the stereocilia. AGs act as open channel
blockers of the MET-channel [100, 101]. Initially, AGs
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Figure 1: Proposed mechanisms of aminoglycoside transport in
the inner ear. Possible entry sites for aminoglycosides into the
scala media include via (1) the Reissner’s membrane, (2) stria
vascularis, and (3) basilar membrane. Published work supports
the notion of entry via the Reissner’s membrane and the stria
vascularis through and between the marginal cells. At the hair cell
level, aminoglycosides can potentially enter via mechanotransducer
channels located on stereocilia of hair cells (A), endocytosis on the
apical or basolateral membranes (A, B, or C), TRP channels (A, B
or C), or ATP receptors (A).
were not considered to be permeable because diameter
estimates of the MET-channel pore were low (0.6 nm) [102].
However, work by Gale and coworkers suggested that larger
molecules could pass through the MET channel [103].
This was quantified by Farris et al. with a new pore size
estimate of 1.25 nm [104], which is large enough to pass
AGs. Marcotti et al. demonstrated directly that AGs could
pass through the channel [92]. Interestingly, this block was
decreased significantly for AG approaching the channel from
the internal as opposed to the external face [92]. As this
diﬀerence between internal and external blocking of AG
makes the MET channel function like a one-way valve,
intracellular accumulation of AGs is promoted and might
explain the increased susceptibility of hair cells compared to
other cell types [94]. The significance of the MET channel as
a major route of AG entry is furthermore supported by the
exacerbation of ototoxic damage with noise exposure [105].
Acoustic stimuli increase the open probability of the MET
channel and thereby, increase AG uptake [106]. Additionally,
the distribution of ototoxic damage with increasing hair
cell susceptibility from apex to base corresponds to the
transduction currents in the cochlea, which are larger in basal
than in apical OHCs and, in general, more decreased in inner
hair cells (IHC) [107–109]. Moreover, fluorescently labeled
gentamicin has been observed first in the tips of hair cell
stereocilia before the fluorescent signal increases in the hair
cell body [87].
Several other ion channels might also contribute to AG
uptake into hair cells. Channels of the transient receptor
potential (TRP) class such as TRPC3, TRPV4, TRPA1, and
TRPML3 are expressed in the cochlea [110–112] and are
permissive to AGs in kidney cells [113, 114]. It is unclear at
this point under what conditions the TRP channels might
be open and whether these channels are expressed in the
plasma membrane or in other cytosolic compartments. The
glycoprotein megalin is another potential mediator for AG
uptake. Megalin is predominantly expressed in the proximal
tubules of the kidney. Megalin is capable of binding AGs
and is also expressed in the inner ear [115]. Therefore, it
was considered a candidate protein for the uptake of AG
into hair cells. However, megalin is a drug receptor engaging
in endocytosis and is not expressed in the organ of Corti
and sensory hair cells [115–117]. Notwithstanding, megalin
has been detected in marginal cells of the stria vascularis,
suggesting a role in the transport of AGs into the inner ear
fluids [116, 117].
3.3. Apoptotic Pathways of Ototoxic Hair Cell Death. Inside
the hair cell, AGs cause damage, either directly or indirectly,
by first inducing disarray of stereocilia and ultimately ending
with apoptotic cell death [118–121]. The presence of AGs
within hair cells leads to increased formation of reactive
oxygen species (ROS) or free radicals [122–125]. A common
mechanism for the formation of ROS is the Fenton reaction:
Fe2+ + H2O2 −→ Fe3+ + HO• +HO−. (1)
Here, the presence of iron salts is required [126]. When
gentamicin combines with iron salts, the gentamicin-iron
complex enhances iron-catalyzed oxidations and, thereby,
directly promotes the formation of ROS [122]. This requires
electrons for which unsaturated fatty acids can act as
electron donors. In return, those fatty acids, predominantly
arachidonic acid, are oxidized to lipid peroxides [125, 127].
As arachidonic acid is an essential fatty acid present in
cellular membranes, ROS can aﬀect membrane fluidity and
permeability [128, 129]. Via lipid peroxidation, ROS can
also aﬀect proteins and nucleic acids thereby disrupting the
activity of enzymes, ion channels, and receptors [128–131].
ROS naturally occur in the cell as a regular byproduct of
cellular metabolism [130–132]. Normally, the cell protects
itself from lethal ROS accumulation with intrinsic antioxi-
dants such as glutathione [132, 133]. This intrinsic protective
system is capable of neutralizing ROS to some extent [134].
When formation of ROS, however, overwhelms the capacity
of these intrinsic protective and repair systems, the cell then
undergoes apoptotic cell death [135, 136].
The mechanism of involvement of mitochondrial muta-
tions in ototoxic hair cell death is not completely understood.
Exposure to AG leads to impairment of RNA translation and
inhibition of protein synthesis within mitochondria [65, 69,
137]. It is further suggested that inhibition of mitochondrial
protein synthesis leads to a decrease in ATP [137]. With the
decrease of energy production, the mitochondrial integrity
is compromised and predispose to a leakage of cytochrome
c and subsequent activation of the apoptotic cascades.
Furthermore, it is hypothesized that the mitochondrial RNA
mutations when exposed to AG cause an increased formation
of ROS, which then promote apoptotic cell death [137].
Independent extrinsic and intrinsic apoptotic path-
ways exist [138, 139]. The extrinsic pathway is mediated
by death receptors including the tumor necrosis factor
(TNF) family. When stimulated, death receptors activate
cysteine-dependent, aspartate-specific proteases also known
as caspases. The prototype of death receptors is the FAS
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(CD95/APO-1) receptor, which activates caspase-8 on stim-
ulation. Caspase-8 in turn initiates a cascade involving the
activation of caspase-3, caspase-6, and caspase-7, which
ultimately execute cellular degeneration [140]. The intrinsic
pathway, in contrast, is the major apoptotic pathway initiated
by aminoglycoside ototoxicity (Figure 2) [120]. The intrinsic
pathway is predominantly triggered by nonreceptor stimuli
such as cytokine deprivation, DNA damage, and cytotoxic
stress [141]. Characteristic for the intrinsic apoptotic path-
way is the permeabilization of the outer mitochondrial
membrane resulting in leakage of proapoptotic factors from
the mitochondrial intermembrane space into the cytoplasm.
Mitochondrial membrane integrity and components of the
intrinsic pathway are regulated by proteins of the B-Cell
Lymphoma-2 (Bcl-2) family [141].
Bcl-2 is the prototype of this equally named protein
family. Studies in other systems report these molecules as key
apoptosis mediators, acting upstream of caspase activation
[142–144]. The Bcl-2 proteins function as a checkpoint
for cell death and survival signals in the mitochondria
(Figure 2). The Bcl-2 protein family can be anti- or pro-
apoptotic [136, 145, 146]; anti-apoptotic Bcl-2 proteins
include Bcl-2 and Bcl-XL [143, 147], whereas pro-apoptotic
Bcl-2 proteins which promote cell death include Bax, Bak,
Bcl-Xs, Bid, Bad, and Bim [143, 147]. Bcl-2 proteins form
hetero- and homodimers within the cell. When a cell is
challenged, the balance between anti- and pro-apoptotic Bcl-
2 proteins regulate whether or not apoptotic cell death is
initiated [148]. Anti-apoptotic Bcl-2 proteins are able to bind
to pro-apoptotic Bcl-2 proteins, thus neutralizing the pro-
apoptotic signal [149]. When the balance moves in favor
of apoptosis, the pro-apoptotic cytoplasmic Bcl-2 member
Bax translocates to the mitochondria, causing pores in the
mitochondrial membrane [143, 144]. This leads to loss of
mitochondrial transmembrane potential, generation of ROS,
and leakage of cytochrome c into the cytoplasm [143, 144,
150–154], thus activating the upstream caspase pathway
as mentioned above. Supporting a role of this pathway in
the inner ear, hair cell loss, and caspase-9 activation were
prevented in utricles from Bcl-2 overexpressing mice when
treated with neomycin [155]. This suggests a role for Bcl-2
in the upstream caspase cascade in aminoglycoside-induced
hair cell death.
Another group of mediators of apoptotic hair cell
death is the stress-activated protein kinases, including the
mitogen-activated protein (MAP) kinases (Figure 2) [120].
A particular group of MAP kinases are c-jun N-terminal
kinases (JNK). These JNKs are located in the cytoplasm
and regulated by c-Jun-interacting protein-1 (JIP-1) [156,
157]. In response to cellular insults, JIP-1 facilitates the
phosphorylation and thus activation of JNK [158–161].
Activated JNK in turn phosphorylates and thereby activates
the transcription factors c-Jun, c-Fos, ELK-1, and activated
transcription factor 2 (ATF-2) in the nucleus and Bcl-2 in
mitochondria [120]. After AG treatment, increases in JNK,
c-Jun, c-FOS, and Bcl-2 have been reported in hair cells
[120, 152, 161, 162]. Activation of the JNK signaling pathway
appears to precede the release of mitochondrial cytochrome
c, which then activates caspases [152, 163].
Aminoglycosides
ROS
Stress kinases
Caspase-3
Cell death
Caspase-9
Mitochondria
Bcl-2
Bcl-XL
Cyto c
Bax
Bak
Bcl-XS
Bid
Bad
Bim
Figure 2: A simplified schematic of the cell death cascade in hair
cells damaged by aminoglycosides. Reactive oxygen species (ROS),
stress kinases, and the caspase family of proteases are activated and
mediate hair cell degeneration caused by aminoglycoside exposure,
whereas overexpression of Bcl-2 protects against caspase activation
and hair cell loss. Aminoglycosides damage the mitochondria and
can result in generation of ROS and activation of stress kinases.
Both ROS and stress kinases can cause cell death directly as well
as amplify insults targeting the mitochondria. The balance between
pro-apoptotic and anti-apoptotic Bcl-2 family members determines
the integrity of the mitochondria. Cytochrome c leaking out of
damaged mitochondria leads to caspase-9 activation, which in turn
activates caspase-3 to execute cell death.
Caspases execute cell death in apoptosis [141]. The
caspase family consists of 14 members in mammals, with
only a subset involved in apoptosis [142, 164]. Caspases can
thus be segregated into upstream and downstream enzymes,
which are normally inactive [136, 164]. Caspases exist in
the cytoplasm normally inactivated by inhibitor of apoptosis
proteins (IAP) [136, 141]. Activation of upstream caspases
occurs by apoptosis-inducing signals such as p53, which
has been shown to activate caspases after administration of
cisplatin. Downstream caspases are activated by upstream
caspases through cleavage of an inactivating prodomain to
produce the mature enzyme [136].
Caspase-8 is an upstream member that is tightly linked
to membrane-associated death domain-containing recep-
tors. When ligands such as Fas ligand or tumor necrosis
factor alpha bind to this receptor, caspase-8 is recruited
intracellularly, leading to clustering and autoactivation of
other caspase-8 molecules [165]. This subsequently causes
activation of downstream caspases such as caspases-3, -6,
and -7. Although caspase-8 is detected in HC after AG
administration [166, 167], it does not play a key role in HC
death, as inhibition of this pathway does not prevent HC
death or prevent caspase-3 activation [166, 168, 169].
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Caspase-9 is an upstream caspase activated by apoptotic
signals from the mitochondria. This pathway is initiated
by cytochrome c release from mitochondria, which then
binds to apoptosis protease activating factor, dATP, in the
cytoplasm and procaspase-9 [164, 170]. This binding causes
cleavage and activation of caspase-9, which subsequently
cleaves and activates downstream caspases, ultimately result-
ing in apoptotic cell death (Figure 2). Activated caspase-9
is detected in cochlear and utricular hair cells after AG
treatment in vitro [151, 166, 167].
Caspase-3 is a primary downstream caspase that executes
the apoptotic program by cleavage of proteins necessary for
cell survival, including Bcl-2, inhibitors of deoxyribonucle-
ases, and cytoskeletal proteins (Figure 2) [171–174]. This
enzyme activation has been detected in HC due to ROS after
AG dosing [150, 151, 166, 167, 175].
Further mechanisms of apoptotic hair cell death follow-
ing AG administration involve activation of NF-κβ as well as
calcium-dependent proteases such as calpains. Inhibition of
NF-κβ in rat cochlear explants after exposure to gentamicin
altered the ratio of activated over inactivated pro-apoptotic
factors such as c-Jun and p38 as well as of anti-apoptotic
factors such as akt [176]. Exposure of mice cochlear cultures
to neomycin resulted in apoptotic DNA fragmentation,
which could be prevented by a calpain inhibitor [177].
Overall, apoptotic death of hair cells due to AG exposure
is complex and our understanding of it has increased in
recent years. A simplified model of the apoptotic cascade in
aminoglycoside damaged hair cells is presented in Figure 2,
but it is important to point out that many components
of the overall cascade and the interactions among these
components are still poorly understood. This complexity is
in part reflected by crosstalks among pathways. Death recep-
tor stimulation, for example, is also capable of activating
the intrinsic pathway despite primary involvement in the
extrinsic pathway [141].
4. Efforts in Hair Cell Protection
With increasing understanding of ototoxic cell death, a
myriad of therapeutic eﬀorts have been proposed to target
various steps of the complex cascades to hair cell death.
Those strategies include inhibition of apoptosis, neutraliza-
tion of ROS, and administration of neurotrophic factors. A
detailed overview of relevant studies including applied drugs,
dosage, and outcome is presented in a table at the end of each
subchapter.
4.1. Inhibition of Apoptotic Enzymes. Permeable caspase
inhibitors such as z-Val-Ala-Asp(O-Me)-CH2F-fluoromethyl
ketone (zVAD) were applied against diﬀerent AGs in a variety
of species. zVAD inhibits by irreversibly binding to the active
site of a broad spectrum of caspases [167]. Caspase inhibitors
conferred significant protection against hair cell damage
from AG, preserving hair cell morphology as well as function
in vitro and in vivo [167, 178–182] (Table 1).
Agents targeting upstream stress kinases in the apoptotic
cascades also prevented AG-induced hair cell death. D-
JNKI-1 is a cell permeable peptide that binds to all three
isoforms of JNK, thereby blocking JNK-mediated activation
of the apoptotic transcription factor c-Jun [156]. Inhibition
of the MAP-JNK pathway by application of D-JNKI-1
prior to treatment with neomycin resulted in significant
protection from hair cell loss in vitro and hearing loss in
vivo [161]. Other JNK inhibitors that successfully prevented
AG ototoxicity are CEP-1347, CEP 11004, and 17β-Estradiol
[152, 183–186] (Table 1).
Targeting the Bcl-2 family as the upstream key mediator
of apoptosis also prevented AG-induced hair cell loss.
Overexpression of the anti-apoptotic Bcl-2 in transgenic
mice significantly decreased hair cell loss and preserved
hearing function following AG exposure in vitro and in vivo
[155, 187]. Inoculation of mouse cochlea with an adenovirus
vector expressing the anti-apoptotic Bcl-XL before treatment
with kanamycin also protected from hair cell loss and
preserved hearing function [188] (Table 1).
Another class of stress-activated proteins are the family
of heat shock proteins (HSPs), which are upregulated in
stressed cells in multiple organ systems. HSPs can not only
prevent protein aggregation by promoting proper folding
of nascent or denaturated polypeptides [189], but also
inhibit apoptosis. Induction of HSP expression in cultured
mouse utricle led to upregulation of HSP-70, HSP-90, and
HSP-27 [190]. Overexpression of HSP-70 in transgenic mice
significantly protected from hair cell loss from neomycin
treatment in vitro, but also significantly protected from
hearing loss and hair cell death in mice injected with
kanamycin over the course of 14 days [191, 192].
Application of anti-apoptotic agents raises several con-
cerns. The protective results of anti-apoptotic drugs are
mainly based on acute studies. Therefore, the sustainability
of therapeutic potential and safety remain to be evaluated
in chronic exposure scenarios. There is evidence that the
protective eﬀects of caspase inhibitors to the inner ear are
short term [167]. Considering that AGs are not metabolized
[7, 34, 73] and remain in the hair cells for months [88, 194],
potential sustainable regimens would conceivably require
long-term treatment. Unfortunately, long-term treatment
with anti-apoptotic drugs bears a potential carcinogenic risk,
as apoptosis has a crucial primary function in preventing
uncontrolled cell proliferation [195]. This carcinogenic risk,
therefore, prohibits potential application in human otologic
patients. Whether this risk is decreased over a long period by
local application to the inner ear remains to be studied. The
therapeutic application of anti-apoptotic agents to rescue
hair cells after AG exposure has not been reported, but is of
further translational interest.
4.2. Neutralization of Reactive Oxygen Species. Aminogly-
cosides form complexes with iron, thereby, catalyzing the
formation of ROS [122]. Competitive blocking of the Fenton
reaction involved by iron chelators, thus, is a reasonable
approach to avoid oxidative damage from the beginning.
Therefore, much eﬀorts aiming at prevention of AG-induced
hair cell death have focused on iron. Administration of
the iron chelators deferoxamine and 2,3-dihydroxybenzoate
before AG exposure significantly attenuated hearing thresh-
old shifts and protected from hair cell loss in vivo [196–198].
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Table 1: Overview of studies performed to protect from aminoglycoside ototoxicity by inhibition of apoptosis. C: Chicken, G: Gerbil,
GP: Guinea Pig, M: Mouse, R: Rat, ZF: Zebrafish; X: in vitro, Y: in vivo; i.m.: intramuscular, i.p.: intraperitoneal, i.t.: intratympanic, s.c.:
subcutaneous; d: day, h: hour; O: no eﬀect, P/PP/PPP: partial, not significant/partial and statistically significant/complete and statistically
significant protection.
Therapy (dose) Aminoglycoside (dose) Species Outcome Reference
zVAD (100 μM, 26 h) Gentamicin (0.1, 0.5, 2mM; 24 h) C, X PPP [167]
zVAD (100 μM, 26 h) PPP
BAF (100 μM, 26 h) Gentamicin (1mM, 6 & 24 h) GP + PPP [178]
Deferoxamine (1mM, 26 h) G, X PPP
zVAD (300 μM, 12 h) Neomycin (10 μM, 3 h) ZF PP [179]
zVAD (local 50, 100 μM or 1.5mg/kg i.m.) Streptomycin (1.2 g/kg; 5 d, i.m.) C, Y
local PP
i.m. P
[180]
zVAD (250 μM, local @ 0.5 μL/h, 14 d)
zLEHD (150 μM, local @ 0.5 μL/h, 14 d)
Gentamicin (12mg/mL, local
@ 0.5 μL/h, 14 d)
GP, Y
PP
PP
[182]
zDEVD (10 or 200 μM, 48 h) PP (200 μM)
zIETD (10 or 200 μM, 48 h) Gentamicin (35 μM, 48 h) R, X O [193]
zLEHD (10 or 200 μM, 48 h) O
zVAD (100 μM, 26 h) M, X PPP
zIETD (100 μM, 26 h) Neomycin (1mM, 24 h) O [166]
zLEHD (100 μM, 26 h) PP
d-JNKI-1 (M 2 μM; GP 10 μM, 1 μL/h local, 7 d)
Neomycin (M 1mM, 24–48 h; GP
300mg/kg i.p. 5 d)
M, X
GP, Y
PPP
PPP
[161]
CEP-11004 (0.5 μM, 84 h) Gentamicin (50 μM, 72 h) R, X PP [184]
CEP-11004 (0.2, 0.4, 1.6, 4.8 μM; 7 h) Neomycin (1mM, 3 h) C, X PP (1.6 μM) [152]
CEP-11004 (1.0 μM; 24 h) Neomycin (1mM, 24 h) M, X PP [183]
Estradiol (1, 10, 100, 1000 nM; 60 h) Gentamicin (100 μM, 48 h) R, X P [185]
CEP-1347 (1mg/kg s.c., 1 x/d, 14 d) Gentamicin (120mg/kg s.c., 1 x/d, 14 d) GP, Y PP [186]
Bcl-2, transgenic Neomycin (1mM, 24 h) M,X PP [155]
Bcl-2, transgenic Gentamicin (40 μg i.t., single dose) M, Y PP [187]
Bcl-X(L), transgenic Kanamycin (800mg/kg, 2 x/d, s.c., 15 d) M, Y PP [188]
HSP 70, transgenic Neomycin (1–4mM, 24 h) M, X PP [191]
HSP-70, transgenic Kanamycin (700mg/kg, 2 x/d, s.c., 14 d) M, Y PP [192]
HSP-70, transgenic Kanamycin (700mg/kg, 2 x/d, s.c., 14 d) M, Y PP [192]
Acetylsalicylate (ASA) is another iron chelator with addi-
tional direct antioxidant properties. ASA prevents cleavage
of PKC zeta, a key regulator of NFκβ activated by exposure to
amikacin [199]. Systemic administration of ASA eﬀectively
protects guinea pigs from gentamicin-induced hearing loss
[200]. As ASA is a long-approved and routinely prescribed
drug, application in human patients is the logical next step.
In randomized, double-blind placebo-controlled studies,
ASA significantly protected human patients from ototoxic
damage without compromising the antimicrobial eﬃcacy of
gentamicin [201–203]. However, ASA itself is ototoxic and
potentially causes tinnitus, vertigo, and hearing loss [204].
Although these symptoms are known to be reversible [204],
AGs remain in hair cells for months [88, 194] and ototoxic
damage can occur after many years [81]. Thus chronic
treatment with ASA appears necessary and ototoxic eﬀects of
both, AGs and ASA, need to be evaluated over a long period.
In this context, recent studies discovered a decrease of activity
in auditory neurons in long-term treatment [205]. Of further
concern is that AGs are frequently prescribed in children
and neonates. ASA, however, is strictly contraindicated in
children as it is associated with Reye’s syndrome, which is
a serious and often fatal disease predominantly aﬀecting the
brain and liver [206–208].
N-Acetylcysteine (NAC) is another drug commonly used
in patients. Beside its mucolytic eﬀect, NAC is also a known
antioxidant. In short-term cultures of guinea pig cochlea,
AG alone caused less than 30% of basal OHC survival but
90% of the apical OHC survived. This observation correlated
with lower levels of the intrinsic antioxidant glutathione in
basal OHC. However, survival of basal OHCwas significantly
improved by cotreatment with NAC as well as glutathione
and salicylate [209]. In hemodialysis patients who received
gentamicin treatment for bacteremia, application of NAC
resulted in significantly less high frequency hearing threshold
shifts compared to a control group receiving gentamicin
alone. Treatment with NAC was continued for one week after
cessation of the gentamicin therapy and the protective eﬀects
persisted after another six weeks [210]. Compared to ASA,
NAC does not demonstrate intrinsic ototoxic side eﬀects.
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A myriad of other agents with known antioxidant
capacity has been tested for protection and treatment of AG
ototoxicity. These agents are primarily antioxidants such as
D-Methionine (D-Met) [211–213] and α-lipoic acid (α-LA)
[214], vitamins such as α-tocopherol (vitamin E) [215–217]
and vitamin C [218] as well as the herbal extracts Gingko
biloba [219] and Danshen [220]. The hormone melatonin,
normally excreted by the pineal gland, also has antioxidant
capacity and successfully protected from AG ototoxicity
[175, 221–223]. An alternative protective strategy against
AG ototoxicity is the upregulation of intrinsic antioxidant
mechanisms such as the superoxide dismutase (SOD) [209,
224, 225] (Table 2).
Overall, antioxidants attenuate ototoxic damage from
AGs. However, the majority of antioxidants did not demon-
strate complete protection from AG ototoxicity [211–213,
215–217, 227, 229] and eﬀects of long-term treatment
remain to be studied.
4.3. Alternative Otoprotective Strategies. There exists a num-
ber of alternative approaches to protect against AG oto-
toxicity. One intriguing approach is moderate exposure
to ototoxic stimuli with the intent to increase intrinsic
antioxidant mechanisms within the ear. Exposure to low
doses of amikacin or gentamicin for 30 days and consecutive
high-dose treatment for another 10 to 12 days resulted in sig-
nificantly less morphologic and functional hair cell damage
[230, 231] (Table 3). However, this bears the undesirable risk
of increased bacterial resistance and, thereby, undermines
the primary antimicrobial purpose of the AG application.
Exposure to moderate noise also protects from gentamicin
ototoxicity in gerbils [232] (Table 3). As this does not
allow for immediate application of AG in therapeutic doses,
applicability in human patients appears diﬃcult.
Other studies successfully target NMDA receptors to
protect auditory nerves [233, 234]. However, the NMDA
receptor antagonists dizocilpine and ifenprodil exist as
maleate and tartrate salts, which carry intrinsic metal
chelating properties [235]. Their vehicle, dimethyl sulfoxide
(DMSO), can also act as a radical scavenger [236]. Therefore,
the results of Basile and coworkers [233, 234] were challenged
by Sha and Schacht [237]. Nonetheless, NMDA antagonists
do interact with receptors of aﬀerent auditory nerve fibers
[238]. Thus, targeting the auditory nerve appears reasonable
as AGs interact with certain nerve synapses. AGs can aggra-
vate myasthenia gravis and cause postoperative respiratory
suppression suggesting a direct neuromuscular blockade
[239–242] (Table 3). Presynaptically, AGs interfere with the
calcium internalization essential for acetylcholine release
[243]. At the postsynaptic level, streptomycin directly blocks
the acetylcholine receptor primarily, whereas neomycin
aﬀects the open probability of the ion channel of the
acetylcholine receptor [244]. Also, in rat and mouse cochlear
cultures, fluorescently tagged gentamicin accumulates in the
aﬀerent auditory nerve fibers in addition to the hair cells
[245].
This direct interaction with the auditory nerve alsomight
explain therapeutic eﬀects by neurotrophic growth factors.
Ciliary neurotrophic factor (CDNF), glial-cell-line-derived
neurotrophic factor (GDNF), brain-derived neurotrophic
factor (BDNF), and neurotrophin 3 (NT-3) demonstrated
partial protective eﬀects against AG ototoxicity [213, 246–
250] (Table 3). The contribution of neurotrophic growth
factors in preventing AG ototoxicity suggests an involvement
of the auditory nerve. However, there is evidence that
the eﬀects of neurotrophic growth factors are short term.
Local application of BDNF (62.5 μg/mL, 0.25 μL/h over 28 d)
to guinea pigs exposed to kanamycin (400mg/kg, single
dose, s.c.) and furosemide (100mg/kg, single dose, i.v.)
demonstrated initial protection from ototoxicity. Cessation
of the therapy, however, resulted in an accelerated neuronal
degeneration and after another 14 d, the survival of BDNF-
treated auditory neurons did not diﬀer from the deafened,
untreated control animals [251].
Ethacrynic acid (EA) is a diuretic which increases
AG ototoxicity when administered simultaneously [252].
Delayed co-treatment with application of EA 12–18 hr after
gentamicin injections in guinea pigs resulted in significantly
protected hair cell function and morphology [253]. The
authors suggest that EA disrupts the blood-labyrinth barrier,
thus creating a gradient promoting eﬄux of AG from the
inner ear fluids back into the bloodstream. However, the
protective eﬀects are time dependent and could not be found
when EA was injected 20 hr after the AG [253]. Moreover,
simultaneous AG and EA in patients resulted in ototoxic
damage after a single treatment [254], thereby excluding EA
as a treatment option.
Overall, prevention of apoptotic hair cell death follow-
ing AG exposure has been targeted eﬀectively on various
levels. Direct inhibition of apoptotic cascades resulted in
functional and morphological preservation of hair cells.
Neutralization of free radicals by antioxidants prevented
activation of apoptotic enzymes. Furthermore, application of
NMDA-receptor antagonists, neurotrophic growth factors,
and sound conditioning have prevented ototoxic hair cell
damage from AG. However, these protective results are
mainly based on acute studies and the sustainability of
therapeutic potential and safety remains to be evaluated in
chronic exposure scenarios or in clinical trials.
5. Potential Targets for Hair Cell Protection
In light of recent insight and increasing understanding of
the mechanisms involved in AG ototoxicity, newer and more
eﬀective targets may be revealed in the near future. Those
target sites involve the mitochondrial rRNA as well as AG
entry into the inner ear fluids and hair cells. Considering
the one-way valve function of the MET channel as a site of
AG entry into hair cells [92, 94], the prolonged persistence
of AG in hair cells poses another obstacle to overcome
[194]. Therefore, avoiding entry of AG into hair cells is
potentially promising. On the level of the MET channel, at
least two possibilities of preventing AG entry exist. The first
one involves a reversible block of the MET channel. The
process of hearing requires depolarization of the inner hair
cell through the MET channel [101, 260, 261]. Blocking of
theMET channel would then prevent hair cell depolarization
and, therefore pause hearing function. Thus, the MET
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Table 2: Overview of studies performed to protect from aminoglycoside ototoxicity by antioxidants. C: Chicken, CH: Chinchilla, G:
Gerbil, GP: Guinea Pig, H: Human, M: Mouse, R: Rat, ZF: Zebrafish; X: in vitro, Y: in vivo; i.m.: intramuscular, i.v.: intravenous, i.p.:
intraperitoneal, i.t.: intratympanic, s.c.: subcutaneous, RWM: round windowmembrane; d: day, h: hour; O: no eﬀect; P/PP/PPP: partial, not
significant/partial and statistically significant/complete & statistically significant protection; T/TT/TTT: partial, not significant/partial and
statistically significant/complete & statistically significant rescue.
Therapy (dose) Aminoglycoside (dose) Species Outcome Reference
Dihydroxybenzoate (100mg/kg, 1 or 2 x/d, i.p.,
21 or 26 d)
Gentamicin (120mg/kg, 1 x/d, s.c., 19 d or
135mg/kg, 1 x/d, s.c., 14 d)
GP PP [196]
Deferoxamine (100mg/kg, 2 x/d, s.c., 28 d)
Dihydroxybenzoate (100mg/kg, 1 x/d, p.o.)
Gentamicin (120mg/kg, 1 x/d, s.c., 19 d) GP
PP
PP
[197]
Dihydroxybenzoate (300mg/kg, 2 x/d, 14-15 d) Kanamycin (400–900mg/kg, 2 x/d, s.c., 15 d) M, Y PP [198]
Aspirin (0.1 or 1.0mg/mL in drinking water, 8 d) Amikacin (500mg/kg, 1 x/d, i.p., 5 d) R, Y PP [199]
Aspirin (3× 500mg/d, p.o., 7 d) Gentamicin (3× 80mg/d, i.v., 7 d) H PP [201]
Aspirin (3× 1 g/d, p.o., 14 d) Gentamicin (total 975–986mg i.v./patient) H PPP [202]
Aspirin (3× 1 g/d, p.o., 14 d) Gentamicin (80–160mg, 2 x/d, i.v., 5–7 d) H PP [203]
NAC (600mg, 2 x/d, p.o., 22–25 d) Gentamicin (2mg/kg/d, i.v., avg. 15 d) H PP [210]
D-Met (300mg/kg/d, i.p., 28 d) Amikacin (200mg/kg, 1 x/d, 28 d) GP, Y PP [211]
D-Met (200mg/kg, 1-2 x/d, s.c., 19 d) Gentamicin (120mg/kg, 1 x/d, s.c., 19 d) GP, Y PP [212]
L-NAME (100 μM, 4 h) PP
[213]D-Met (50mM, 4 h) Gentamicin (2mg/mL, 4 h) GP, X PP
Leupeptin (1mM, 4 h) PP
α-LA (100mg/kg/d, i.m., 15 d) Amikacin (400mg/kg, 1 x/d, i.m., 15 d) GP, Y PP [214]
Edaravone (3mg/kg/d, i.p., 2–14 d) Tobramycin (160mg/kg, 1 x/d, s.c., 14 d) R, Y PPP, TTT [226]
Resveratrol (10 μM or 100 μM, 24 h) Gentamicin (0.4mM, 24 h) R, X PP [227]
α-Tocopherol (100mg/kg, 1 x/d, i.m., 14 d) Gentamicin (100mg/kg, 1 x/d, i.m. <14 d) GP, Y PP [216]
α-Tocopherol (100mg/kg, 1 x/d, i.m., 14 d) Gentamicin (100mg/kg, 1 x/d, i.m. <14 d) GP, Y PP [215]
α-Tocopherol (100mg/kg, 1 x/d, i.m., 14 d) Gentamicin (100mg/kg, 1 x/d, i.m. <14 d) GP, Y PP [217]
Glutathione (10mM, 1 h) PP
Dithioerythritol (10mM, 1 h) PP
Vitamin C (10mM, 1 h) Gentamicin (1mM, 1 h) GP, X PP [218]
Trolox (4mM, 1 h) PP
Phenylene Diamine (10mM, 1 h) PP
Glutathione (0.6mL 0.3M, p.o., 14 d) Gentamicin (100mg/kg, 1 x/d, i.m., 14 d) GP, Y PP [228]
Ginkgo biloba (10mg/kg, 30min to RWM or
1× 100mg/kg i.p.)
Gentamicin (5mg/kg, 45min to RWM or
5mg/kg, 24 h to RWM)
GP, Y P [219]
Danshen (1–20mg/kg, 2 x/d, s.c., 15 d) Kanamycin (700mg/kg, 2 x/d, s.c., 15 d) M, Y PP [220]
Melatonin (10mg/L in drinking water p.o., 12 d
or 250 μg, s.c., 1 x/d, 5–12 d)
Gentamicin (160mg/kg, 1 x/d, i.m., 5 d)
Tobramycin (200mg/kg, 1 x/d, i.m., 5 d)
R, Y PP [223]
Melatonin (0.4 or 4.0mg/kg, 1 x/d, i.p., 14 d) Amikacin (600mg/kg, 1 x/d, i.m., 14 d) R, Y P (0,4mg) [221]
Melatonin (0.3 l/kg, 1 x/d, i.m., 17 d) Gentamicin (120mg/kg, 1 x/d, i.m., 17 d)
GP, X +
Y
PP [222]
Melatonin (10, 50, 100 μM, 1–7 d) Gentamicin (1mM, 48 h) R, X PP [175]
M40403 (30 μM, 24 h) Gentamicin (0.5 or 1mM, 24 h) M, X PP [225]
Cu/Zn SOD, transgenic Kanamycin (400mg/kg, s.c., 10 d) M, Y PP [209]
Cu/Zn SOD, transgenic
Mn SOD, transgenic
Kanamycin (250mg/kg, s.c., single dose)
Ethacrynic Acid (40mg/kg, i.v., single dose)
GP, Y
O (Cu/Zn)
PP (Mn)
[224]
channel block has to be temporary. MET channel blockers
have been tested successfully in vitro [104]. Yet their in
vivo eﬀects are largely unknown. The second possibility of
preventing AG entry through the MET channel involves
steric modification of the chemical structure of AGs. From
electrophysiological measurements, the narrowest part of
the MET channel pore has been estimated to be 1.25 nm
[104]. As dihydrostreptomycin is capable of blocking the
MET channel [92], the diﬀerence in the dimensions of the
MET channel and certain AGs appears to be small. Therefore,
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Table 3: Overview of studies with alternative strategies to protect from aminoglycoside ototoxicity. C: Chicken, CH: Chinchilla, G: Gerbil,
GP: Guinea Pig, M: Mouse, R: Rat, X: in vitro, Y: in vivo; i.m.: intramuscular, i.v.: intravenous, i.p.: intraperitoneal, i.t.: intratympanic, s.c.:
subcutaneous; d: day, h: hour, q12 h: every 12 h; O: no eﬀect; P/PP/PPP: partial, not significant/partial and statistically significant/complete
and statistically significant protection.
Therapy (dose) Aminoglycoside (dose) Species Outcome Reference
BDNF (10 ng/mL, 4 h) Gentamicin (2mg/mL, 4 h) GP, X PP [213]
Dizocilpine (1mg/kg/d, osmotic
pump, 14 d)
Ifenprodil (10mg/kg/d, osmotic
pump, 14 d)
Neomycin (50mg/kg, 1 x/d, s.c., 14 d) or
Kanamycin (250mg/kg, 1 x/d, s.c., 21 d)
GP, Y
PP
PP
[233]
Dizocilpine (1mg/kg, 1 x/d, s.c.,10 d) Streptomycin (400mg/kg, 1 x/d, s.c., 10 d) R, Y PP [234]
CTNF (0.44 g/kg, 1 x/d, s.c., 30 d) Gentamicin (80mg/kg, 1 x/d, i.m., 30 d) GP, Y PP [249]
BDNF (1 μg, pellet in semicircular
canal, with AG or 1 week later, over
1–8 weeks)
Gentamicin (50 μg, pellet in semicircular canal, over
1–8 weeks)
CH, Y
P
TT
[246]
BDNF (100 μg/mL, local, pump @
0.25 μL/h, 30 d)
NT-3 (100 μg/mL, local, pump @
0.25 μL/h, 30 d)
Kanamycin (400mg/kg, 1 x/d, i.p., 5 d) GP, Y
O (BDNF)
PP (NT-3)
[248]
L-NAME (100 μM, 8 h)
BDNF (10 ng/mL, 8 h)
Gentamicin (2mg/mL, 8 h) GP, X
PP
PP
[247]
Isosorbide (1mM, 8 h) Gentamicin (2mg/mL, 8 h) GP, X PP [255]
MK 801 (1mg/kg, 3 x before pump
implantation) +/− NT-3 (local in
pump @ 300 ng/h over 14 d)
Amikacin (300mM, local pump @ 5 μL/h, 24 h) GP, Y
P (MK 801)
PP (MK +
NT)
[256]
GDNF (10 μM, 72–96 h) Neomycin (0.6mM, 72 h) R, X P (X)
[250]GDNF (50 ng/mL, local pump @
0.5 μL/h or single dose 0.1mg, i.t.)
Kanamycin (200mg/kg, s.c., single dose) + Ethacrynic
Acid (40mg/kg, i.v., single dose)
GP, Y PP (Y)
GDNF + TGF-1, transgenic
Kanamycin (150mg/kg, s.c., single dose) + Ethacrynic
Acid (40mg/kg, i.v., single dose)
GP, Y PP [257]
GDNF, transgenic Gentamicin (8mg, i.t., single dose) GP, Y PP [258]
GDNF, transgenic
Kanamycin (200mg/kg, s.c., single dose) + Ethacrynic
Acid (40mg/kg, i.v., single dose)
GP, Y PP [259]
Gentamicin (10mg/kg, 1 x/d, i.m.,
30 d)
Gentamicin (160mg/kg, 1 x/d, i.m., 10 d) GP, Y PP [230]
Amikacin (20mg/kg, 1 x/d, i.m., 30 d) Amikacin (400mg/kg, 1 x/d, i.m., 10 d) GP, Y PP [231]
2 Octave-band noise (81 dB SPL for
21 d)
Gentamicin (445 μg, local to RWM over 14 d) G, Y P [232]
Ethacrynic Acid (40mg/kg, i.v., single
dose, 12–18 h )
Gentamicin (125mg/kg, 1–20 injections q12h, i.m.) GP, Y PP [252]
widening of the AG diameter by binding of inert molecules
on sites irrelevant for antimicrobial activity appears a
promising strategy to prohibit passage of AGs through the
MET channel into the hair cells. As the passage through
the bacterial membrane is self-promoting and depends on
the relative positive charge of the AG [42–47, 262–264], the
intended increase of size should not aﬀect bacterial uptake of
the AG as long as the polarity and the charge of the new AG
molecule remains the same. However, interference with the
antimicrobial activity due to sterical impairment of binding
to the bacterial ribosome needs to be tested.
Another target lies in preventing AG from entering the
inner ear fluids. AGs enter the inner ear fluids through the
stria vascularis [87]. Blocking the passage of AG requires
the identification of the transport mechanism in the blood-
labyrinth barrier.
AGs are potent antibiotics with limited application due
to their side eﬀects. Until the problem of AG ototoxicity
is solved, it is crucial to be judicious in prescribing AGs
for defined clinical indications. Furthermore, it is important
for clinicians to remember the genetic mutations as a cause
for increased susceptibility to ototoxic damage. However,
indiscriminate genetic screening is not cost-eﬀective at
present. Instead, a thorough history of the patient and their
family regarding ototoxic symptoms from antibiotics helps
assessing the individual risk. Independent from genetic
mutations, patients should undergo a baseline hearing test
including ultrahigh frequencies prior to AG administration
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to allow for early and unambiguous assessment of potential
ototoxic damage.
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